China’s 2025 Labor Day Sees Surge in Inbound and Outbound Travel Spending via Alipay and Other Alipay+ Partner Payment Apps
6.5.2025 11:43:00 CEST | Business Wire | Press Release
Data from Alipay and other Alipay+ partner payment apps indicates a notable increase in both outbound and inbound tourism spending in China during the 2025 Labor Day holiday (Golden Week).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250505144383/en/
The Myeongdong shopping area in South Korea welcomes travelers to pay with Alipay and other Alipay+ partner payment apps.
Outbound Travel: Chinese tourists explore local experiences through digital platforms in overseas destinations
Through Alipay+, a unified wallet gateway with cross-border payment and digitization services developed by Ant International, users of 36 e-wallets in Asia and Europe—including Chinese travelers—can use their own home payment apps across over 70 markets without the need to exchange currency or carry cash. During China's Labor Day holiday, global Alipay+ merchants have joined Alipay in an exclusive campaign to lure travelers.
The top destinations for Chinese travelers, based on total Alipay spending, are Hong Kong SAR, Japan, Macao SAR, South Korea, Thailand, Malaysia, Singapore, France, Canada, and Italy.
Thanks to Alipay+'s 100 million-strong and diverse global merchant network, Chinese tourists are increasingly seeking more personalized, local experiences. Switzerland recorded the highest average Alipay spending per user, while in South Korea, average spending exceeded USD 100—driven in part by the growing trend of traveling for cosmetic surgery. In addition, the growing desire for immersive local travel experiences is driving increased use of local transportation, with Alipay transactions rising 53% year-over-year. Public transit has become the most frequently used Alipay service among travelers. Taking buses and subways with Alipay is especially popular in Hong Kong SAR and Macao SAR, where travelers are already familiar with using it for daily commutes. Other emerging trends include buying train tickets in Europe and unlocking shared bikes in Japan with Alipay.
Furthermore, Alipay’s real-time tax refund service saw a 33% year-on-year increase in the refund value per transaction, while the number of claims for Alipay’s instant discount offer increased by 46% compared to the New Year’s Day holiday.
Inbound Travel: Visa-free entry, updated tax refund policies, and new payment options attract international travelers
Since September 2023, the Alipay+ solutions have supported 13 leading payment apps1 in Asia to serve their roaming users across Alipay’s extensive merchant network in China.
Thanks to China’s updated tax refund and visa-free policies, more international travelers are heading to the country. During the Labor Day holiday, both the number of transactions and the total spending by travelers using the 13 overseas e-wallets rose by over 100% year-on-year.AlipayHK topped the list for total spending, followed by Malaysia’s Touch ’n Go e-Wallet, Kazakhstan’s Kaspi.kz, Macao SAR’s MPay, and Thailand’s TrueMoney.
With Alipay+, international travelers may also bind their Visa, Mastercard, American Express, JCB, Discover®, Diners Club International®, and UnionPay International credit or debit cards to Alipay for a seamless travel experience in China. This enables smooth payments and access to a wide range of digital services on the Alipay platform, including ride-hailing, hotel bookings, and plane or train ticket purchases.
Alipay Tap!—a contactless payment and customer engagement solution introduced by Alipay in China in June 2024—has also quickly become a preferred payment method among international travelers to China. The solution is essentially a simplified QR-code method that enables users to access services hosted on Alipay simply by tapping a merchant’s terminal or an Alipay Tap! Tag, without needing to open an app, scan a code, or navigate multiple screens. As of April 2025, Alipay Tap! had attracted over 100 million users in China within just 11 months of launch. During the Labor Day holiday, travelers from the 54 countries covered by China’s 240-hour visa-free transit policy spent 50% more via Alipay Tap! compared to the same period in April.
About Alipay+
Ant International's Alipay+ is a unified wallet gateway with cross-border payment and digitization services that help connect global merchants to consumers. Consumers enjoy seamless payments a broad choice of deals and the convenience of digital services using their preferred payment app/e-wallet while travelling abroad. Many small and medium-sized businesses already use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
About Alipay
As the world becomes increasingly digital, Alipay has evolved from a trusted e-wallet into an all-in-one digital platform for daily services, connecting more than one billion consumers to over 80 million merchants across China. Alipay offers users a secure, seamless mobile payment experience and integrates over 10,000 services across sectors like travel, healthcare, tourism, and entertainment. With digital tools like Alipay Tap!, mini-programs, lifestyle accounts, Alipay enables merchants, institutions, and independent software vendors (ISVs) to enhance operational efficiency and effectiveness. In addition, Alipay is developing a new AI-driven open platform by integrating AI agents to deliver smarter, more personalized services to its users as well as facilitating the digital transformation of the service sector.
____________________ 1 The 13 payment apps include AlipayHK (Hong Kong SAR, China), Kaspi.kz (Kazakhstan), MPay (Macao SAR, China), Touch ’n Go eWallet (Malaysia), Hipay (Mongolia), NayaPay (Pakistan), Changi Pay (Singapore), OCBC Digital (Singapore), Kakao Pay (South Korea), Naver Pay (South Korea), Toss Pay (South Korea), TrueMoney (Thailand), GCash (The Philippines). |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250505144383/en/
Contacts
Media Inquiries
Yinan Duan
globalcomms@antgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom